Pembrolizumab with chemotherapy for treating HER2-negative advanced gastric or gastro-oesophageal junction adenocarcinoma [ID4030]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 19 June 2024
Zolbetuximab with chemotherapy for untreated claudin 18.2-positive HER2 negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma [ID5123]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 23 October 2024
Pembrolizumab with chemotherapy and surgery for treating resectable gastric or gastro-oesophageal junction cancer [ID2696]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with trastuzumab and chemotherapy for untreated HER2-positive advanced gastric or gastro-oesophageal junction cancer [ID3742]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma ID1629Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tislelizumab for previously treated advanced oesophageal squamous cell cancer [ID4070]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC